Early blood test linked to later MS disability worsening
By MS Buddy ·
Summarized from JAMA neurology, Apr 2023 · PubMed · DOI. AI-generated summary. Not medical advice.
Observational study · 578 people after a first MS-like attack at Spanish hospitals
Research by Enric Monreal, Luisa María Villar and 26 colleagues at Universidad de Alcalá, Institut d'Investigacions Biomèdiques August Pi i Sunyer and Universitat de Barcelona and 7 other institutions in Spain.
Can a blood test after a first MS-like attack predict later disability worsening?
Key Takeaway
Higher levels of a blood marker after a first MS-like attack were linked to greater disability worsening years later.

What They Found
Researchers measured a blood marker of nerve damage within the first year after a first MS-like attack. People with higher levels were more likely to have disability that worsened and stayed worse for six months. They were also more likely to reach a higher level of disability on a doctor's rating scale. The link appeared in both groups of patients studied at Spanish hospitals. Among people with high marker levels, stronger MS treatments were linked to a lower risk of disability worsening.
Who Should Care and Why
The study followed people in Spain after their first MS-like attack. It focused on whether an early blood test could help predict later disability. Researchers checked patients at least every six months. They followed patients for about seven years, on average. The findings may help identify people at greater risk of disability worsening, but the test's role in treatment decisions remains uncertain.
Important Considerations
This observational study followed 578 people and did not assign treatments. You cannot tell from these findings whether stronger MS treatments caused the lower risks seen among people who received them. The study does not show whether using this blood test to choose treatment improves outcomes.
AI-generated summary — for informational purposes only, not medical advice
Read the original abstract
Published in JAMA neurology by et al.. Reproduced from the PubMed record.
The value of serum neurofilament light chain (sNfL) levels for predicting long-term disability in patients with multiple sclerosis (MS) remains controversial. To assess whether high sNfL values are associated with disability worsening in patients who underwent their first demyelinating MS event. This multicenter cohort study included patients who underwent their first demyelinating event suggestive of MS at Hospital Universitario Ramón y Cajal (development cohort; June 1, 1994, to September 31, 2021, with follow-up until August 31, 2022) and 8 Spanish hospitals (validation cohort; October 1, 1995, to August 4, 2020, with follow-up until August 16, 2022). Clinical evaluations at least every 6 months. The main outcomes were 6-month confirmed disability worsening (CDW) and an Expanded Disability Status Scale (EDSS) score of 3. Levels of sNfL were measured in blood samples obtained within 12 months after disease onset using a single molecule array kit. The cutoffs used were sNfL level of 10 pg/mL and a standardized score (z score) of 1.5. Multivariable Cox proportional hazards regression models were used to evaluate outcomes. Of the 578 patients included in the study, 327 were in the development cohort (median age at sNfL analysis, 34.1 years [IQR, 27.2-42.7 years]; 226 female [69.1%]) and 251 patients were in the validation cohort (median age at sNfL analysis, 33.3 years [IQR, 27.4-41.5 years]; 184 female [73.3%]). The median follow-up was 7.10 years (IQR, 4.18-10.0 years). Levels of sNfL greater than 10 pg/mL were independently associated with higher risk of 6-month CDW and an EDSS of 3 in the development cohort (6-month CDW: hazard ratio [HR], 2.39; 95% CI, 1.39-4.12; P = .002; EDSS of 3: HR, 4.12; 95% CI, 2.18-7.77; P < .001) and the validation cohort (6-month CDW: HR, 1.61; 95% CI, 1.07-2.42; P = .02; EDSS of 3: HR, 2.03; 95% CI, 1.23-3.33; P = .005). Highly effective disease-modifying treatments were associated with lower risks of 6-month CDW and an EDSS of 3 in patients with high baseline sNfL values. This cohort study found that high sNfL values obtained within the first year of disease were associated with long-term disability worsening in MS, suggesting that sNfL level measurement may help identify optimal candidates for highly effective disease-modifying treatments.
Categories
Explore more research
Related MS research

11/18/2026
An adjusted MRI scan found more veins within MS brain lesions in 17 people with MS. It improved scan
Read More
11/16/2026
A planned study will use detailed brain scans and blood tests to explore why relapsing-remitting MS
Read More
1/1/2026
After a car crash, brain and spine scans revealed signs of MS in an 18-year-old male. Further tests
Read More
11/14/2026
An opinion paper explains why MS brain scans can show tissue loss without proving nerve signal failu
Read More
11/15/2026
In 70 people with MS in Brazil, blood tests often showed signs of past viral exposure. Results did n
Read More
11/12/2026
In a study of 601 people in Japan after first optic nerve inflammation, some later had MS. Others ha
Read MoreNot all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.
